http://www.amirapharm.com/index.htm

Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease. Our discovery team is building on unparalleled insights into the bioactive lipid pathways, a complex signaling processes controlling many condictions including asthma and cardiovascular disease.

8-Jan-2009: Amira Pharmaceuticals, Inc. expands its Scientific Advisory Board and appoints Dr. Paul Anderson, Professor Jerold Chun and Professor Andrew Tager.<more> 6-Jan-2009: Amira announces the successful completion of GLP toxicity studies for a novel DP2 antagonist. Lead candidate on track for IND submission first half of 2009.<more> 9-June-2008: Amira Pharmaceuticals Hires Industry Veteran for CFO Position<more>		Three years since launch; $40 million invested; five novel lead compounds discovered. Download our fact sheet for an overview of Amira. PDF Keep pace with developments at Amira by signing up for regular email alerts. Sign up here.

© Copyright Amira Pharmaceuticals 2005-2008. All rights reserved